Estrogens and angiotensin-converting enzyme (ACE) inhibitors can also trigger attacks, the latter by interfering with metabolism of bradykinin. curing the disorder. The effectiveness of these options is rapidly improving in many cases, and their risks are decreasing. Given the very high costs of treating HAE, some of these curative options may become feasible in the next decade. Keywords: hereditary angioedema types I and II, gene therapy, CRISPR/Cas9, liver, metabolic diseases == Introduction == Hereditary angioedema (HAE) is rare disorder caused by mutations of the SERPING1 or F12 genes. Disulfiram It was first described by Quincke in 1882 (1) and subsequently by Osler (2). Affected patients experience recurrent abdominal pain or swelling, which can be fatal if it involves the larynx. Current estimates suggest a prevalence of about 1: 70, 000 in the general population (3). There is no obvious ethnic variation in the disorder. Typically, symptoms begin in late childhood and become worse after puberty. Therefore , the disorder has Disulfiram a much higher morbidity and mortality in adults compared with children. Hereditary angioedema is an autosomal dominant disorder, where heterozygotes are symptomatic. There are examples of variable penetrance and expressivity of the gene, where some affected family members may not manifest any symptoms. As discussed below, there are recent data suggesting sequence variations in genes involved in the production or catabolism of bradykinin might also influence the severity of the disorder. This phenotypic variability can contribute to the delay in diagnosis of the condition, which is typically about 8 years (4, 5). There is a high mortality rate in HAE patients prior to diagnosis (6). Angioedema attacks can be triggered by trauma, stress, and hormonal changes associated with menstruation or pregnancy in affected women. There is evidence for systemic effects of local activation of the contact phase (7). Estrogens and angiotensin-converting enzyme (ACE) inhibitors can also trigger attacks, the latter by interfering with metabolism of bradykinin. ACE is the dominant enzyme responsible for degrading bradykinin. It is clear that androgen treatment can reduce the frequency and severity of the attacks (8). However , androgens are contraindicated in children and pregnant women and can cause troublesome virilizing adverse effects in women (8). In the last few years, there have been remarkable advances in management of the disorder (9). Use of purified or recombinant C1 inhibitor (C1 INH) is effective in treating severe attacks, especially if administered early. Other Mouse monoclonal to IL-10 drugs, such as bradykinin receptor, antagonists, and kallikrein inhibitors, have also proven to be effective in treating acute attacks (10). Unfortunately, the high cost of these newer medications places them beyond the reach of most developing countries (Table1). In spite of these advances, a cure for this potentially fatal disorder has been elusive. == Table 1 . == Comparison of currently available treatments for HAE types 1 and 2 . The costs for these medicines vary in different countries. Recurrent infections or autoimmunity are not a feature of the disorder. Yet, in the most recent IUIS/WHO classification of primary immunodeficiency disorders, HAE is listed as an immunodeficiency disorder because the mutated gene functions as an Disulfiram inhibitor of the complement cascade (11). The dominant biochemical problem is impaired function of the contact phase leading to unregulated production of bradykinin (12), which in turn causes the angioedema. Disulfiram Although useful for making the diagnosis, the complement cascade is mostly a bystander in swelling attacks. Dysfunction of the complement system does not lead to immediate symptoms or major complications in HAE. Sequence variations in SERPING1.